Nyx-2925
Diabetic Peripheral Neuropathic Pain
AptinyxPhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 81/ 100
Competitive context
28 Active assets in the Diabetic Peripheral Neuropathic Pain cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Duloxetine Aga Khan University | Phase 4 | A |
Duloxetine Eli Lilly and Company | Phase 4 | BBB |
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)- Aziende Chimiche Riunite Angelini Francesco S.p.A | Phase 4 | BBB |
ds-5565 Bangladesh Medical University | Phase 4 | BBB |
Capsaicin Corporacion Parc Tauli | Phase 4 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →